Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 severe or critically meta-analysis

Jamaati
  IRCT20151227025726N1		 RCTdexamethasonestandard of careCOVID-19 severe or criticallysome concern
25/25 suggested
  • inconclusive 19 % increase in deaths,death D28 (PE) with a moderate degree of certainty due to some concern in risk of bias
  • inconclusive 38 % increase in mechanical ventilation (PE) with a moderate degree of certainty due to some concern in risk of bias
  • suggested 3.9-fold increase in radiologic improvement (14-day) with a moderate degree of certainty due to some concern in risk of bias
CODEX (Tomazini)
  NCT04327401		 RCTdexamethasonestandard of careCOVID-19 severe or criticallysome concern
151/148 inconclusive
    DEXA-COVID19
          NCT04325061    		 RCTdexamethasonestandard of careCOVID-19 severe or criticallylow
    		7/12 inconclusive
      Edalatifard
              IRCT20200404046947N1      		 RCTmethylprednisolonestandard of careCOVID-19 severe or criticallyhigh
      		34/34 suggested
      • suggested 71 % decrease in deaths,deaths (time to event analysis only) but with a low degree of certainty due to high risk of bias
      • suggested 11.0-fold increase in clinical improvement but with a low degree of certainty due to high risk of bias
      REMAP-CAP, fixed 7-day course
              NCT02735707      		 RCTHydrocortisonestandard of careCOVID-19 severe or criticallyhigh
      		143/108 safety concern
      • inconclusive 43 % increase in clinical improvement (PE) but with a low degree of certainty due to high risk of bias
      • statistically significant 1.7-fold increase in death or ventilation but with a low degree of certainty due to high risk of bias
      REMAP-CAP, shock-dependent course
              NCT02735707      		 RCTcorticosteroidsstandard of careCOVID-19 severe or criticallyhigh
      		152/108 inconclusive
      • inconclusive 22 % increase in clinical improvement (PE) but with a low degree of certainty due to high risk of bias
      Steroids-SARI
              NCT04244591      		 RCTmethylprednisolonestandard of careCOVID-19 severe or criticallysome concern
      		24/23 inconclusive
        2 studies excluded by filtering options (0 RCT / 2 OBS)

        PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
        Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

         

        - About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons